Education
About Us
Working with TipRanks
Follow Us
Renascience Inc. (JP:4889)
:4889
4889 Stock Chart & Stats
Day’s Range― - ―
52-Week Range¥263.00 - ¥2,944.00
Previous CloseN/A
Volume77.30K
Average Volume (3M)2.12M
Market Cap
¥34.26B
Enterprise ValueN/A
Total Cash (Recent Filing)¥1.84B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)302.0
Beta0.37
Next Earnings
Aug 13, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.20
Shares Outstanding12,711,700
10 Day Avg. Volume2,359,150
30 Day Avg. Volume2,116,553
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)7.02
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
4889 FAQ
What was Renascience Inc.’s price range in the past 12 months?
Renascience Inc. lowest stock price was ¥263.00 and its highest was ¥2944.00 in the past 12 months.
What is Renascience Inc.’s market cap?
Renascience Inc.’s market cap is ¥34.26B.
When is Renascience Inc.’s upcoming earnings report date?
Renascience Inc.’s upcoming earnings report date is Aug 13, 2025 which is in 29 days.
How were Renascience Inc.’s earnings last quarter?
Currently, no data Available
Is Renascience Inc. overvalued?
According to Wall Street analysts Renascience Inc.’s price is currently Overvalued.
Does Renascience Inc. pay dividends?
Renascience Inc. does not currently pay dividends.
What is Renascience Inc.’s EPS estimate?
Renascience Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renascience Inc. have?
Renascience Inc. has 12,711,700 shares outstanding.
What happened to Renascience Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Renascience Inc.?
Currently, no hedge funds are holding shares in JP:4889
Company Description
Renascience Inc.
Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.
Technical Analysis
StemRIM Inc.
―
ReproCELL Inc.
―
StemCell Institute
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―